Overactive Bladder Market Overview, Trends, and Key Drivers in 2025
The 7 major overactive bladder markets reached a value of USD 2.6 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3.8 Billion by 2035, exhibiting a growth rate (CAGR) of 3.3% during 2025-2035.
The Global Overactive Bladder (OAB) Market Study reports that the growth within the OAB market in 2025 is attributed to the global population becoming older, better awareness, and improvements on treatment options. Individuals suffering from ‘overactive bladder’ syndrome have to deal with the aggravating symptom of an uncontrollable urge to urinate. This often results in involuntary leakage. Along with a large portion of the elderly population, women too are affected. The condition affects the lives of millions of people worldwide. The therapies used for treating OAB continue to grow with improved diagnostic rates and stigma surrounding the disorder hesitantly declining. One of the most noticeable changes in the Overactive Bladder Market in 2025 is the development of modern delivery systems for drugs and new dosage forms. Pharmaceutical companies have created medications in the form of extended release tablets, as well as delivery systems in the form of transdermal patches. These enhancements have proven to be better than the previous anticholinergic tablets that have proven to cause dry mouth, constipation, and other side effects. Improvements in compliance and tolerability are just some of the additional benefits provided.
The adoption of β3-adrenergic agonists to treat OAB, a new class of drugs, is another important change that is affecting the market. These medications calm the bladder muscle, which decreases both the frequency and urgency of urination. The ongoing success of mirabegon’s drugs motivates other companies to develop new molecules within the same class that are safer and more effective. Non-pharmaceutical methods are also making way into the market. PTNS and sacral neuromodulation are newer forms of medication neuromodulation therapy that have been proven to work for patients who do not respond to medication. These technologies provide hope for patients who suffer from refractory OAB and make up a new and expanding market segment. The evolution of the condition is also being aided by the digital health ecosystem. Mobile applications that monitor patient symptoms, bladder training programs, and remote consultations are becoming more prevalent in managing the condition. These resources enhance patient participation as well as aid physicians in crafting individualized treatment regimens, making them more precise. More publicity focus and improved access to medical care, particularly in developing countries, add new dynamics to the medical market. Public health policies along with support by advocacy groups are encouraging people to seek medical attention, which increases the population that can be treated.
From a regional perspective, North America still leads the market for overactive bladder treatment owing to the high rates of diagnosis, strong reimbursement, and further worsening healthcare facilities. However, it is Asia-Pacific region which has the highest potential as a market, due to growing population, rapid urbanization, and advances in the delivery of health services. A noticeable shift in the Still's Disease market would be driven by increasing awareness, access to better screening and biologic therapies in 2025. Still’s Disease is a rare and auto inflammatory disease with systemiic symptoms like high grade fevers, joints pain, rashes and widespread inflammation. This condition is underdiagnosed due to its low prevalence rate and overlap with many other diseases, but that is gradually changing.
Request for a sample of this report: https://www.imarcgroup.com/overactive-bladder-market/requestsample
Countries Covered:
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country:
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the overactive bladder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the overactive bladder market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current overactive bladder market drugs and late-stage pipeline drugs.
In-Market Drugs:
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the overactive bladder market has been studied in the report with the detailed profiles of the key players operating in the market.
1. AbbVie
2. Pfizer
3. AbbVie
4. Astellas Pharma
5. Kyorin Pharmaceutical/Urovant Sciences
6. Bayer
7. Urovant Sciences
8. Taiho Pharmaceutical
Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7291&flag=A
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
**About Us:
**IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
**Contact US:
IMARC Group
**134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
